Sanie Samuel Sogoyan Sesay

Biography

Dr. Sanie Samuel Sogoyan Sesay is a medical doctor with an infectious disease and epidemiology background who is currently working as Transformation Leader in Sanofi Vaccines Research & Development. He completed his MBChB degree from the College of Medicine and Allied Health Sciences of the University of Sierra Leone, followed by pre- and post-registration training at the Sierra Leone Medical and Dental Council (SLMDC), where he is in the SLMDC permanent register. He is also in the permanent register of the Gambian Medical and Dental Council and Medical Council of Malawi. He received a Master of Science in Epidemiology from the London School of Hygiene and Tropical Medicine (LSHTM), a Diploma in Tropical Medicine and Hygiene (DTM&H) from The Royal College of Physicians (London), a Diplomate of the London School of Hygiene and Tropical Medicine, and a Doctor of Philosophy in Tropical Medicine from the Liverpool School of Tropical Medicine (LSTM).

Before joining Sanofi, he was a Malaria Capacity Development Consortium/Wellcome Trust post-doctoral fellow at the Clinical Sciences Department of the Liverpool School of Tropical Medicine and a lecturer in the Department of Public Health of the College of Medicine, University of Malawi. He also lectured previously at the DTM&H and East African DTM&H course of LSHTM. He also previously lectured on the Clinical Development of Vaccines at the DAS Management of Clinical Trials MSc course at the Faculty of Medicine, University of Geneva. He is also a lecturer in the Research and Development Faculty of Sanofi Pasteur. Dr. Sesay has more than 20 years' experience in the conduct clinical trials of drugs and vaccines.

He is also a member of several scientific associations, including the American Association for the Advancement of Sciences, the International Society for Infectious Diseases, the International Epidemiological Association, and the Brighton Collaboration. He possesses a Six Sigma Green Belt, Lead Certified, has co-authored 11 manuscripts and two clinical manuals, and holds a patent for the development of a genetically modified live attenuated RSV intranasal vaccine.